UNSPSC 51342713: Atazanavir sulfate

This classification denotes a protease inhibitor with the molecular formula C38H52N6O7.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4MT4VIE29P, chemically known as 2,5,6,10,13-pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3s,8s,9s,12s)-, sulfate (1:1) (salt) but more generally known as atazanavir sulfate, which bears US NIH Compound Identifier 158550.

UNSPSC 51342713 Atazanavir sulfate is a Commodity code that nominally covers a specific antiretroviral pharmaceutical product, but recent state and local solicitations tagged under this code show minimal alignment with its narrow scope. The opportunities posted in the block reflect broader pharmaceutical procurement activity spanning emergency medical supplies, pharmacy benefit management programs, and multi-source generic pharmaceuticals—work that falls outside the specific drug substance named in the code. State and local procurement offices appear to use this code inconsistently or as a catch-all for pharmaceutical contracting rather than as a targeted category for atazanavir sulfate itself. Issuing bodies include county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The geographic spread covers Florida, Texas, Minnesota, and Oregon through cooperative purchasing arrangements.

Recent opportunities in the block include the City of Tampa's March 2026 IFB for medical and first aid supplies (1-year base term with two optional renewals, estimated $700,000, SLBE set-aside with 5 percent bid discount) for use by the Tampa Fire Department Rescue Division; the Texas Health and Human Services Commission's April 2026 RFI on direct-to-manufacturer pharmacy programs seeking vendor capabilities for negotiated net pricing without rebates; and the Minnesota Multistate Cooperative Purchasing Alliance's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026 and a two-year base term. A Seminole County, Florida IFB from 2023 (posted June 30, 2026 but with a due date of July 26, 2023) sought naloxone and drug deactivation systems with quarterly deliveries. The code shows little relevant recent activity specifically for atazanavir sulfate; the tagged opportunities reflect general pharmaceutical and medical supply procurement that does not match the Commodity's nominal scope.